Literature DB >> 3709267

Human pharmacokinetics and distribution in various tissues of ceftriaxone.

F Fraschini, P C Braga, G Scarpazza, F Scaglione, O Pignataro, G Sambataro, C Mariani, G C Roviaro, F Varoli, G Esposti.   

Abstract

Multiple-dose pharmacokinetics of ceftriaxone were investigated in 7 patients with bronchopneumonia using an intramuscular regimen of 1 g given every 24 h for 7 days. Serum, sputum, and urine samples were collected serially following the first dose (day 1) and last dose (day 7). Mean peak serum concentrations of ceftriaxone occurred at 2 h on both days and were 67.8 and 75.1 micrograms/ml, respectively, on day 1 and day 7. Ceftriaxone had a half-life of 6.9 h on day 1 and 7.4 h on day 7. The half-life of ceftriaxone in sputum was 5.9 and 6.6 h, respectively, on days 1 and 7. Approximately 50% of the dose of ceftriaxone was recovered in the urine within 24 h on day 1, 60% on day 7. Tissue distribution of ceftriaxone was determined in 103 patients following intramuscular administration of a single 1-gram dose at different times up to 24 h prior to surgery. High concentrations of ceftriaxone were found in lung, tonsil, middle ear mucosa, and nasal mucosa, and therapeutic levels of ceftriaxone persisted for 24 h after administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709267     DOI: 10.1159/000238415

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  12 in total

1.  Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; J Bauchet; F Faurisson; P Gehanno; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

2.  Single-Arm Open-Label Clinical Trial of Two Grams of Aztreonam for the Treatment of Neisseria gonorrhoeae.

Authors:  Lindley A Barbee; Olusegun O Soge; Negusse Ocbamichael; Angela LeClair; Matthew R Golden
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 3.  Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction.

Authors:  Arlene C Seña; Laura Bachmann; Christine Johnston; Teodora Wi; Kimberly Workowski; Edward W Hook; Jane S Hocking; George Drusano; Magnus Unemo
Journal:  Lancet Infect Dis       Date:  2020-06-19       Impact factor: 25.071

4.  Double-blind randomized study of 1 g versus 2 g intravenous ceftriaxone daily in the therapy of community-acquired infections.

Authors:  S Segev; R Raz; E Rubinstein; H Shmuely; D Hassin; N Rosen; E Platau; S Ben Assuli; S Pitlik
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-10       Impact factor: 3.267

Review 5.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  Liquid Chromatography Mass Spectrometry Detection of Antibiotic Agents in Sputum from Persons with Cystic Fibrosis.

Authors:  Tara Gallagher; Stefan Riedel; Joseph Kapcia; Lindsay J Caverly; Lisa Carmody; Linda M Kalikin; Junnan Lu; Joann Phan; Matthew Gargus; Miki Kagawa; Simon W Leemans; Jason A Rothman; Felix Grun; John J LiPuma; Katrine L Whiteson
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

Review 7.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration.

Authors:  R N Brogden; A Ward
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

Review 8.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

9.  Pharmacokinetics and protein binding of ceftriaxone during pregnancy.

Authors:  P Bourget; H Fernandez; V Quinquis; C Delouis
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

10.  Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections.

Authors:  G Satta; G Cornaglia; G Foddis; R Pompei
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.